HEADER HYDROLASE/HYDROLASE INHIBITOR 17-MAY-05 1ZPK TITLE CRYSTAL STRUCTURE OF THE COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, TITLE 2 I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE- TITLE 3 PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2 COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEASE RETROPEPSIN; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: HIV-1 PROTEASE; COMPND 5 EC: 3.4.23.16; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 5 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 6 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 8 EXPRESSION_SYSTEM_PLASMID: PET24A KEYWDS HIV, PROTEASE, PEPTIDOMIMETIC INHIBITOR, HYDROLASE-HYDROLASE KEYWDS 2 INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR J.DUSKOVA,T.SKALOVA,J.DOHNALEK,H.PETROKOVA,J.HASEK REVDAT 5 23-AUG-23 1ZPK 1 REMARK REVDAT 4 20-OCT-21 1ZPK 1 REMARK SEQADV SHEET LINK REVDAT 3 13-JUL-11 1ZPK 1 VERSN REVDAT 2 24-FEB-09 1ZPK 1 VERSN REVDAT 1 25-APR-06 1ZPK 0 JRNL AUTH J.DUSKOVA,T.SKALOVA,J.DOHNALEK,H.PETROKOVA,J.HASEK JRNL TITL MUTATIONAL STUDY OF PSEUDOPEPTIDE INHIBITOR BINDING TO HIV-1 JRNL TITL 2 PROTEASE; ANALYSIS OF FOUR X-RAY STRUCTURES JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 1.65 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.65 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.159 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.156 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.253 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 1090 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 21836 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.148 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.145 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.236 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 4.900 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 898 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 18225 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1526 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 53 REMARK 3 SOLVENT ATOMS : 160 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 1701.5 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 1645.0 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 21 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 16137 REMARK 3 NUMBER OF RESTRAINTS : 20476 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.007 REMARK 3 ANGLE DISTANCES (A) : 0.026 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.047 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.026 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.037 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.043 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.007 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.002 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.072 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.000 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: MOEWS & KRETSINGER, J.MOL.BIOL. 91 (1973) 201-228 REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH & HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: ANISOTROPIC SCALING APPLIED BY THE REMARK 3 METHOD OF PARKIN, MOEZZI & HOPE, J.APPL.CRYST.28(1995)53-56 REMARK 4 REMARK 4 1ZPK COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 01-JUN-05. REMARK 100 THE DEPOSITION ID IS D_1000032992. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 12-APR-00 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 4.4 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.934 REMARK 200 MONOCHROMATOR : DIAMOND C 111 REMARK 200 OPTICS : MICROFOCUSING MIRRORS - TESTING REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 21955 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.650 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -999.00 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 200 DATA REDUNDANCY : 6.900 REMARK 200 R MERGE (I) : 0.03900 REMARK 200 R SYM (I) : 0.03900 REMARK 200 FOR THE DATA SET : 48.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.65 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.69 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.8 REMARK 200 DATA REDUNDANCY IN SHELL : 3.00 REMARK 200 R MERGE FOR SHELL (I) : 0.37000 REMARK 200 R SYM FOR SHELL (I) : 0.37000 REMARK 200 FOR SHELL : 2.300 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: 1A9M REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 41.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.10 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.5 M NACL, 0.1 M NA CITRATE, 10% REMARK 280 GLYCEROL, PH 4.4, MICROSEEDING, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 61 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+1/3 REMARK 290 3555 -X+Y,-X,Z+2/3 REMARK 290 4555 -X,-Y,Z+1/2 REMARK 290 5555 Y,-X+Y,Z+5/6 REMARK 290 6555 X-Y,X,Z+1/6 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 27.47067 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 54.94133 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 41.20600 REMARK 290 SMTRY1 5 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 5 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 68.67667 REMARK 290 SMTRY1 6 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 13.73533 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5790 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9290 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -49.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 600 REMARK 600 HETEROGEN REMARK 600 REMARK 600 THE INHIBITOR 0ZS IS A PSEUDOPEPTIDE WITH THE HYDROXYETHYAMINE REMARK 600 ISOSTERE IN THE R CONFIGURATION REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 NA B 502 NA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASP B 130 OD1 REMARK 620 2 HOH B 308 O 98.2 REMARK 620 3 HOH B 362 O 90.7 119.5 REMARK 620 N 1 2 REMARK 630 REMARK 630 MOLECULE TYPE: PEPTIDE-LIKE INHIBITOR REMARK 630 MOLECULE NAME: N-{(2R,3S)-3-[(TERT-BUTOXYCARBONYL)AMINO]-2-HYDROXY- REMARK 630 4-PHENYLBUTYL}-L-PHENYLALANYL-L-ALPHA-GLUTAMYL-L-PHENYLALANINAMIDE REMARK 630 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 630 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 630 REMARK 630 M RES C SSSEQI REMARK 630 0ZS A 201 REMARK 630 SOURCE: NULL REMARK 630 TAXONOMY: NULL REMARK 630 SUBCOMP: BOC T00 GLU PHE NH2 REMARK 630 DETAILS: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 0ZS A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL B 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NA B 502 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1FQX RELATED DB: PDB REMARK 900 COMPLEX OF HIV-1 PROTEASE WITH A RELATED INHIBITOR (WT-SE) REMARK 900 RELATED ID: 1M0B RELATED DB: PDB REMARK 900 COMPLEX OF HIV-1 PROTEASE WITH A RELATED INHIBITOR (WT-OE) REMARK 900 RELATED ID: 1LZQ RELATED DB: PDB REMARK 900 COMPLEX OF HIV-1 PROTEASE WITH A RELATED INHIBITOR (I8-OE) REMARK 900 RELATED ID: 1IIQ RELATED DB: PDB REMARK 900 COMPLEX OF HIV-1 PROTEASE WITH A RELATED INHIBITOR (WT-SQ) REMARK 900 RELATED ID: 1Z8C RELATED DB: PDB REMARK 900 COMPLEX OF HIV-1 PROTEASE WITH A RELATED INHIBITOR (I11-RE) REMARK 900 RELATED ID: 1ZBG RELATED DB: PDB REMARK 900 COMPLEX OF HIV-1 PROTEASE WITH A RELATED INHIBITOR (I8-RE) REMARK 900 RELATED ID: 1ZJ7 RELATED DB: PDB REMARK 900 RELATED ID: 1ZLF RELATED DB: PDB REMARK 900 RELATED ID: 1ZSF RELATED DB: PDB REMARK 900 RELATED ID: 1ZSR RELATED DB: PDB DBREF 1ZPK A 1 99 UNP P03367 POL_HV1BR 69 167 DBREF 1ZPK B 101 199 UNP P03367 POL_HV1BR 69 167 SEQADV 1ZPK VAL A 71 UNP P03367 ALA 139 ENGINEERED MUTATION SEQADV 1ZPK THR A 82 UNP P03367 VAL 150 ENGINEERED MUTATION SEQADV 1ZPK VAL A 84 UNP P03367 ILE 152 ENGINEERED MUTATION SEQADV 1ZPK VAL B 171 UNP P03367 ALA 139 ENGINEERED MUTATION SEQADV 1ZPK THR B 182 UNP P03367 VAL 150 ENGINEERED MUTATION SEQADV 1ZPK VAL B 184 UNP P03367 ILE 152 ENGINEERED MUTATION SEQRES 1 A 99 PRO GLN ILE THR LEU TRP GLN ARG PRO LEU VAL THR ILE SEQRES 2 A 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET SER LEU PRO SEQRES 4 A 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE LEU ILE GLU SEQRES 6 A 99 ILE CME GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO THR ASN VAL ILE GLY ARG ASN LEU LEU THR SEQRES 8 A 99 GLN ILE GLY CYS THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP GLN ARG PRO LEU VAL THR ILE SEQRES 2 B 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET SER LEU PRO SEQRES 4 B 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE LEU ILE GLU SEQRES 6 B 99 ILE CME GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO THR ASN VAL ILE GLY ARG ASN LEU LEU THR SEQRES 8 B 99 GLN ILE GLY CYS THR LEU ASN PHE MODRES 1ZPK CME A 67 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 1ZPK CME B 167 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE HET CME A 67 16 HET CME B 167 10 HET 0ZS A 201 102 HET CL B 501 1 HET NA B 502 1 HETNAM CME S,S-(2-HYDROXYETHYL)THIOCYSTEINE HETNAM 0ZS N-{(2R,3S)-3-[(TERT-BUTOXYCARBONYL)AMINO]-2-HYDROXY-4- HETNAM 2 0ZS PHENYLBUTYL}-L-PHENYLALANYL-L-ALPHA-GLUTAMYL-L- HETNAM 3 0ZS PHENYLALANINAMIDE HETNAM CL CHLORIDE ION HETNAM NA SODIUM ION FORMUL 1 CME 2(C5 H11 N O3 S2) FORMUL 3 0ZS C38 H49 N5 O8 FORMUL 4 CL CL 1- FORMUL 5 NA NA 1+ FORMUL 6 HOH *160(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLY B 186 THR B 191 1 6 SHEET 1 A 4 GLN A 2 ILE A 3 0 SHEET 2 A 4 THR B 196 ASN B 198 -1 O LEU B 197 N ILE A 3 SHEET 3 A 4 THR A 96 ASN A 98 -1 N THR A 96 O ASN B 198 SHEET 4 A 4 GLN B 102 ILE B 103 -1 O ILE B 103 N LEU A 97 SHEET 1 B 8 LYS A 43 GLY A 49 0 SHEET 2 B 8 GLY A 52 ILE A 66 -1 O VAL A 56 N LYS A 45 SHEET 3 B 8 HIS A 69 VAL A 77 -1 O VAL A 77 N ARG A 57 SHEET 4 B 8 VAL A 32 LEU A 33 1 N LEU A 33 O LEU A 76 SHEET 5 B 8 VAL A 84 ILE A 85 -1 O VAL A 84 N VAL A 32 SHEET 6 B 8 GLN A 18 LEU A 24 1 N LEU A 23 O ILE A 85 SHEET 7 B 8 LEU A 10 ILE A 15 -1 N ILE A 13 O LYS A 20 SHEET 8 B 8 GLY A 52 ILE A 66 -1 O GLU A 65 N LYS A 14 SHEET 1 C 8 TRP B 142 GLY B 149 0 SHEET 2 C 8 GLY B 152 ILE B 166 -1 O VAL B 156 N LYS B 145 SHEET 3 C 8 HIS B 169 VAL B 177 -1 O VAL B 171 N ILE B 164 SHEET 4 C 8 VAL B 132 LEU B 133 1 N LEU B 133 O LEU B 176 SHEET 5 C 8 VAL B 184 ILE B 185 -1 O VAL B 184 N VAL B 132 SHEET 6 C 8 GLN B 118 LEU B 124 1 N LEU B 123 O ILE B 185 SHEET 7 C 8 LEU B 110 ILE B 115 -1 N ILE B 113 O LYS B 120 SHEET 8 C 8 GLY B 152 ILE B 166 -1 O GLU B 165 N LYS B 114 LINK C ILE A 66 N CME A 67 1555 1555 1.33 LINK C CME A 67 N GLY A 68 1555 1555 1.33 LINK C ILE B 166 N CME B 167 1555 1555 1.33 LINK C CME B 167 N GLY B 168 1555 1555 1.34 LINK OD1 ASP B 130 NA NA B 502 1555 1555 2.70 LINK O HOH B 308 NA NA B 502 1555 1555 2.64 LINK O HOH B 362 NA NA B 502 1555 1555 2.49 SITE 1 AC1 33 ARG A 8 LEU A 23 ASP A 25 GLY A 27 SITE 2 AC1 33 ALA A 28 ASP A 29 ASP A 30 ILE A 47 SITE 3 AC1 33 GLY A 48 GLY A 49 ILE A 50 PHE A 53 SITE 4 AC1 33 PRO A 81 THR A 82 HOH A 301 HOH A 392 SITE 5 AC1 33 HOH A 415 HOH A 416 LEU B 123 ASP B 125 SITE 6 AC1 33 GLY B 127 ALA B 128 ASP B 129 ASP B 130 SITE 7 AC1 33 ILE B 147 GLY B 148 GLY B 149 ILE B 150 SITE 8 AC1 33 PRO B 181 THR B 182 HOH B 302 HOH B 327 SITE 9 AC1 33 HOH B 410 SITE 1 AC2 3 GLY B 173 THR B 174 ASN B 188 SITE 1 AC3 3 ASP B 130 HOH B 308 HOH B 362 CRYST1 62.483 62.483 82.412 90.00 90.00 120.00 P 61 12 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.016004 0.009240 0.000000 0.00000 SCALE2 0.000000 0.018480 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012134 0.00000